Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Patent law (2)
- Access to information (1)
- Anticommons (1)
- Competition (1)
- Copyright expansion (1)
-
- Copyright law (1)
- Drugs (1)
- Empirical studies (1)
- Fair use (1)
- Federal Circuit (1)
- File sharing (1)
- Flexibility (1)
- Generic drugs (1)
- Internet (1)
- Inventions (1)
- KSR International Co. v. Teleflex Inc. (1)
- Nonobviousness (1)
- Patent & Trademark Office (1)
- Patent applications (1)
- Patent infringement (1)
- Patentability (1)
- Pharmaceuticals (1)
- Research and development (1)
- Scientific research (1)
- Section 107 (1)
- Technology (1)
- Transaction costs (1)
- United States Supreme Court (1)
Articles 1 - 3 of 3
Full-Text Articles in Law
Noncompliance, Nonenforcement, Nonproblem? Rethinking The Anticommons In Biomedical Research, Rebecca S. Eisenberg
Noncompliance, Nonenforcement, Nonproblem? Rethinking The Anticommons In Biomedical Research, Rebecca S. Eisenberg
Articles
A decade ago the biomedical research community was sounding alarm bells about the impact of intellectual property (IP) rights on the ability of scientists to do their work. Controversies and delays in negotiating terms of access to patented mice and genes, databases of scientific information, and tangible research materials all pointed toward the same conclusion: that IP claims were undermining traditional sharing norms to the detriment of science. Michael Heller and I highlighted one dimension of this concern: that too many IP rights in "upstream" research results could paradoxically restrict "downstream" research and product development by making it too costly …
Pharma's Nonobvious Problem, Rebecca S. Eisenberg
Pharma's Nonobvious Problem, Rebecca S. Eisenberg
Articles
This Article considers the effect of the recent decision of the U.S. Supreme Court in KSR International Co. v. Teleflex, Inc. on the nonobviousness standard for patentability as applied to pharmaceutical patents. By calling for an expansive and flexible analysis and disapproving of the use of rigid formulas in evaluating an invention for obviousness, KSR may appear to make it easier for generic competitors to challenge the validity of drug patents. But an examination of the Federal Circuit's nonobviousness jurisprudence in the context of such challenges reveals that the Federal Circuit has been employing all along the sort of flexible …
Billowing White Goo, Jessica D. Litman
Billowing White Goo, Jessica D. Litman
Articles
The title of this symposium is the question: "Fair Use: "Incredibly Shrinking" or Extraordinarily Expanding?" I'd argue that the answer to the question is "no." Fair use isn't doing either. The size of the fair use footprint has stayed remarkably constant over the past 30 or even 50 years. What has expanded, extraordinarily, is the size of rights granted by the copyright law. It may seem as if fair use is either expanding or shrinking, because the greater reach of copyright has made a bunch of uses potentially fair that weren't even potentially infringing 50 years ago. In order to …